Search results
Results from the WOW.Com Content Network
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [ 2 ] [ 5 ] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.
The mirvetuximab, which has been submitted for FDA approval, is being developed as a monotherapy or a standalone treatment for ovarian cancer. [7] [8] Other products currently in clinical-stage development include: [9] IMGN853, (mirvetuximab soravtansine) targeting FRα, and using DM4. [10] IMGN529, targeting CD37 for Non-Hodgkin lymphoma (NHL ...
AbbVie has pinned its hopes on Elahere, which it acquired as part of a $10 billion buyout of ImmunoGen in November last year, as its top-selling arthritis treatment Humira faces newer rivals.
Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer. [1] [2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big ...
AbbVie and Genentech are both commercializing the drug within the United States, but only AbbVie has rights to do so outside of the U.S. [20] According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion.
AbbVie has also agreed to pay Landos shareholders an additional up to $11.14 per share, or around $75 million in total, contingent on certain clinical development milestones.
This page was last edited on 8 December 2023, at 11:54 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.